Dr Rahul Banerjee discusses ASH 2025 and bispecific antibodies in myeloma, including data from MajesTEC-3, IFM2021-01, and ...

Researchers assessed changes in the prevalence of diversity language in NIH-awarded grants following the US election in 2024.

In this study, researchers aimed to determine whether ctDNA is detectable in other bodily fluids besides blood, and to characterize any ctDNA they were able to detect.

Significant treatment options are changing the management of CLL, according to research presented at the ASH Annual Meeting 2025.

The Food and Drug Administration (FDA) has granted traditional approval to Imdelltra ® (tarlatamab-dlle) for the treatment of adults with extensive stage small cell lung cancer (ES-SCLC) with disease ...

In this study, researchers sought to determine the impact of the FDA’s Accelerated Approval pathway among patients with solid tumors.

Use of tanning beds more than doubles the risk of developing melanoma by increasing the mutation burden in melanocytes, including at skin sites with ...

Investigators evaluated atezolizumab combined with bevacizumab and non–platinum-based chemotherapy for patients with recurrent ovarian cancer.

The current study assesses whether the MNW could address global disparities in oncology education by reaching low- and middle-income countries and if it was able to advance gender inclusivity in ...

Overall survival data showed a 50% reduction in the risk of death with the regimen compared with surgery alone.

Cancer patients and survivors are more likely to report housing and utility insecurity than those who do not have a history of cancer, according research ...

Man patients with MIBC are ineligible for or refuse SOC cisplatin. SunRISe-4 evaluated neoadjuvant gemcitabine intravesical system (TAR-200) plus cetrelimab or cetrelimab monotherapy for pathologic ...